<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>OPUS 4 Latest Documents RSS Feed</title>
    <description>Latest documents</description>
    <link>http://publikationen.ub.uni-frankfurt.de/index/index/</link>
    <pubDate>Fri, 09 Sep 2011 13:31:01 +0200</pubDate>
    <lastBuildDate>Fri, 09 Sep 2011 13:31:01 +0200</lastBuildDate>
    <item>
      <title>Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases</title>
      <link>http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/22676</link>
      <description>Severe acute graft versus host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation. Human mesenchymal stromal cells (MSCs) play an important role in endogenous tissue repair and possess strong immune-modulatory properties making them a promising tool for the treatment of steroid-refractory GvHD. To date, a few reports exist on the use of MSCs in treatment of GvHD in children indicating that children tend to respond better than adults, albeit with heterogeneous results. We here present a review of the literature and the clinical course of two instructive pediatric patients with acute steroid-refractory GvHD after haploidentical stem cell transplantation, which exemplify the beneficial effects of third-party transplanted MSCs in treatment of acute steroid-refractory GvHD. Moreover, we provide a meta-analysis of clinical studies addressing the outcome of patients with steroid-refractory GvHD and treatment with MSCs in adults and in children (n = 183; 122 adults, 61 children). Our meta-analysis demonstrates that the overall response-rate is high (73.8%) and confirms, for the first time, that children indeed respond better to treatment of GvHD with MSCs than adults (complete response 57.4% vs. 45.1%, respectively). These data emphasize the significance of this therapeutic approach especially in children and indicate that future prospective studies are needed to assess the reasons for the observed differential response-rates in pediatric and adult patients. Additional file 1: MSCs expansion and release criteria.his file contains a detailed description of the MSCs expansion and release criteria for Case A and Case B.</description>
      <author>Caroline M. Wernicke; Thomas G. P. Grunewald; Hendrik Juenger; Selim Kuçi; Zyrafete Kuci; Ulrike Köhl; Ingo Mueller; Michaela Döring; Christina Peters; Anita Lawitschka; Hans-Jochem Kolb; Peter Bader; Stefan Burdach; Irene Teichert- von Lüttichau</author>
      <category>article</category>
      <guid>http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/22676</guid>
      <pubDate>Fri, 09 Sep 2011 13:31:01 +0200</pubDate>
    </item>
  </channel>
</rss>
